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ORIGINAL ARTICLE
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ABSTRACT
Salmonellosis ranks among the major diseases of commercial poultry, and its presence in
poultry flocks is responsible for economic losses and risks related to public health. Vaccines
are an important tool within integrated programmes to control salmonellosis. The purpose of
this study was to assess cross-protection provided by the Poulvac® ST vaccine in the control
of Salmonella Heidelberg in experimentally challenged 3- and 21-day-old birds. Eighty birds
were identified and separated into four treatments (T1: vaccinated and challenged at 3 days
of age, T2: unvaccinated and challenged at 3 days of age, T3: vaccinated and challenged at
21 days of age, and T4: unvaccinated and challenged at 21 days of age). The inoculum was
produced from a Brazilian field strain of SH. At the end of the experiment, caecum and liver/
spleen samples were collected for quantitative and qualitative analysis of SH, respectively.
Analysis of the liver/spleen showed that Poulvac® ST significantly (P≤ 0.05) reduced the
percentage of SH positivity in the group challenged at 3 days of age, while in the group
challenged at 21 days this difference was almost considered significant (P = 0.1818). On
the other hand, there was no statistically significant difference in SH count in the caecum
(CFU/g) in the group challenged at 3 days, but for the group challenged at 21 days the SH
counts were significantly (P≤ 0.05) lower in the vaccinated group when compared to the
positive control.
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Introduction
Salmonellosis ranks among the most critical food-
borne diseases affecting international trade in poultry,
and is used as a criterion for product quality (OIE,
2015). Bacteria of this genus have been identified as a
major cause of food poisoning in humans (BRASIL,
2003; Mead et al., 2010).
SalmonellaHeidelberg (SH) is a significant source of
non-typhoidal Salmonella infection and has been
found in several Brazilian states where industrial poul-
try production is widespread, causing concerns about
potential risks to public health (Dickel, 2004; Borsoi
et al., 2006). According to the latest results of the
Pathogen Reduction Plan and European Union Rapid
Alert System for Food and Feed, SH is often present
in positive samples taken from Brazilian poultry pro-
ducts (Freitas, 2011; RASFF, 2014).
Studies examining experimental inoculation of birds
have demonstrated that the behaviour of SH resembles
that of Salmonella Enteritidis, which can generate bac-
teria counts in both the intestine (caeca) and the viscera
(liver); additionally, the curve to quantify the positivity
of the two analysed serotypes was almost identical 72 h
after inoculation (Borsoi et al., 2011). For all analysis
times, SH counts in the intestines exceeded those in
the viscera. These results demonstrate the challenge
faced by the poultry sector in attempting to control
SH, and the risks related to positive testing in poultry
products, since this microorganism is present in con-
siderable quantities in both the intestine and the viscera
(Piao et al., 2007;Wollin, 2007; Gantois et al., 2008). The
SH in Brazil has asymptomatic manifestation in positive
birds and its presence offers a risk just for humans.
Poulvac® ST is a genetically modified live vaccine
developed from a strain of Salmonella enterica subsp.
enterica serovar Typhimurium (STM-1) (Alderton
et al., 1991; Coloe et al., 1994). This serovar produces
antigens in the configuration of lipopolysaccharide
and flagella, which are the same as those seen in
other group B salmonellas (such as SH). This similarity
in the somatic and flagellar antigens indicates a possi-
bility of good heterologous immune response. The vac-
cine aims to protect chickens to reduce transmission to
humans.
The objective of this study was to assess the effec-
tiveness of Poulvac® ST in controlling S. enterica
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subsp. enterica serovar Heidelberg in broiler chickens,
in both the intestines and in the viscera.
Materials and methods
Poultry and treatments
Eighty one-day-old broiler chicks of both genders were
separated into four treatments (T1: vaccinated and chal-
lenged at 3 days of age; T2: unvaccinated and challenged
at 3 days of age; T3: vaccinated and challenged at 21 days
of age; T4: unvaccinated and challenged at 21 days of
age); these chicks from a Cobb Slow line breeder lineage,
commonly used in Brazilian broiler companies, came
from a flock certified to be free from Salmonella spp.
When the chicks arrived from the supplier, the card-
board floor of the box was analysed to assess the presence
or absence of Salmonella spp., using the standard meth-
odology indicated by the Brazilian Ministry of Agricul-
ture, Livestock, and Food Supply (Directive 126 of
November 6, 1995) (BRASIL, 1995).
The birds in all groups were identified on the day
they were assigned into groups, and were fed and
watered using tubular feeders and bell-type watering
stations (chick food and watering stations were used
up to seven days of age). Throughout the experiment,
birds were given free access to food and water.
This protocol was submitted to the Zoetis Ethics and
Animal Welfare Committee for approval prior to the
experiment, and was approved in process 07-15-70AQO.
Vaccination and placement
The study was done in the Experimental Laboratory of
Mercolab, located in Cascavel, Paraná State, Brazil.
Immediately after the birds arrived, they were weighed
and vaccinated (Table 1). Vaccination was conducted
via spraying with Poulvac® ST (batch 002/14 manufac-
tured 08/14, expiration 02/16). A total volume of 40 ml
was sprayed on the 40 chicks (T1 and T3) on the first
day of life. The number of doses was one dose/bird
with a minimum amount of 3 × 107 colony-forming
units (CFU)/dose. The vaccine was diluted with a
free chlorine inactivator containing non-toxic blue
dye (batch 045/14 manufactured May/14, expiration
May/16).
The vaccinated birds were placed together with their
respective control birds in two pens (T1 + T2 and T3 +
T4) and were marked with paint to allow identification.
Just in the second dose of the vaccine, at 14 days of age,
the birds were separated in the same room by a
movable fence to revaccinate only the tagged birds.
One day after vaccination, the fence was removed.
The purpose of allowing the birds to co-mingle was
to validate the independence assumption and the
analytical methods used.
The birds remained in 2.6 m² pens on new wood
shavings (floor pens) in closed rooms during the
experimental period. Plant pelleted feed without any
Salmonella inhibitory ingredients (e.g. organic acids,
prebiotics, or probiotics) was provided. Care was
taken to prevent cross contamination by wearing per-
sonal protective equipment: shoe covers, gowns, hair
nets, and gloves. Both rooms used were identical and
located side by side with independent entrance and
exit. Personal protective equipment was changed
when moving between rooms following the order
from T3 + T4 room to T1 + T2 room. Both the wood
shavings and the rooms were sampled for the presence
of Salmonella spp. before the start of the experiment.
Vaccine
Poulvac® ST is a commercial vaccine produced by Zoe-
tis (Madison, NJ, USA). It contains a live non-virulent
strain of AWC 591 Salmonella Typhimurium in lyo-
philized form with a titre of ≥3 × 107 CFU/dose. This
variant of S. Typhimurium was altered by the deletion
of two genes, aroA and serC. The deletion of these
genes results in an organism that retains the structure
of the cell wall and flagellum, which keeps immunizing
antigens intact.
Challenge
The challenge was performed with a SH strain isolated
from the field. This sample was rendered resistant to
antibiotics (nalidixic acid and novobiocin), which
were incorporated into brilliant green agar to inhibit
gut microbiota and facilitate counting. SH was grown
in BHI broth for 18–24 h at 37°C until reaching a con-
centration of 1.0 × 109 CFU/ml; serial dilution was then
performed until a concentration of 1.0 × 106 CFU/ml
was achieved (Pickler et al., 2012). For birds in groups
1 and 2, 0.5 ml of this culture was inoculated orally at 3
Table 1. Parameters assessed and age at collection in different treatments.
Activity/Parameter assessed Day 0 Day 2 Day 3 Day 7 Day 12 Day 14 Day 21 Day 28
Body weight T1, T2, T3, T4 T1, T2, T3, T4
Vaccination (1st dose) T1, T3
Cloacal Swab for Poulvac ST detection T1, T3 T1, T3 T1, T3
Challenge (SH) T1, T2 T3, T4
Vaccination (2nd dose) T1, T3
SH count (caecum) T1, T2, T3, T4
SH isolation (liver/spleen) T1, T2, T3, T4
Note: T1 (vaccinated and challenged at 3 days of age), T2 (unvaccinated and challenged at 3 days of age), T3 (vaccinated and challenged at 21 days of age), T4
(unvaccinated and challenged at 21 days of age).
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days of age, and at 21 days of age for birds in groups 3
and 4 (Table 1). This dose of challenge was adminis-
tered based on previous work done with Brazilian
strain of SH (pilot test). The birds and environmental
conditions were monitored daily.
Laboratory analyses
In order to count the Salmonella spp, at 28 days of age,
the samples collected from the caecum and liver were
macerated, weighed, and serially diluted in saline sol-
ution at a proportion of 1:10 until a dilution of 10−5
was achieved. Next, 0.1 ml of each dilution was seeded
into brilliant green agar (which also contained 12.5 μg/
ml of nalidixic acid and 20 μg/ml of novobiocin) with a
Drigalski inoculation spatula and incubated at 36 ± 1°C
for 18–24 h. After incubation, the dishes were read and
colonies were counted. Those that were suspected to be
Salmonella were selected for biochemical and serologi-
cal antigenic confirmation.
To detect SH in the organ samples (liver and spleen)
at 28 days of age, the conventional procedure for isolat-
ing Salmonella (pre-enrichment) was carried out
according to Brazilian directive 126 (BRASIL, 1995).
To detect the Poulvac® ST vaccine strain, eight indi-
vidual samples collected from cloacal swabs, in group 1
and 3, at days 2, 7, and 12, were subjected to real-time
polymerase chain reaction analysis (RT-PCR) using a
Rotor Gene SYBR Green PCR kit (Qiagen). Based on
the sequence of the aroA gene region of the genome
of the strain used in Poulvac® ST, a pair of oligonucleo-
tides (primers) was designed that exclusively amplify a
280 bp fragment of the vaccine’s DNA and do not
detect other field isolates of Salmonella spp. One of
the oligonucleotides is based on the IS10 element that
is only present in the vaccine strain.
The oligonucleotides used for detection of the vac-
cine were:
Oligonucleotide 1–5′ CGG CAT TAC CGA GAA
ACA GT 3′
Oligonucleotide 2–5′ AATAA CTGCA GTGAT
CATAT GACAA GATGT GT 3′
The model for each challenge day (T1 and T3) was a
completely random design with bird as the experimen-
tal unit. So each challenge day was separately analysed
as a completely random design with only two treat-
ments. So there was only one possible contrast for
each day. All hypotheses were conducted with signifi-
cance of P≤ 0.05 using a two-tailed test. For positive
liver/spleen testing, Fisher’s exact test was used. The
counts for SH colonies in the caecum (CFU/g) were
analysed using a generalized linear model (negative
binomial distribution). Statistical analysis of body
weights was done by F test at P≤ 0.05 using software
SAS version 9.4, SAS Institute Inc., Cary, NC, USA.
Results
Samples taken from the environment, from the birds
on the first day, and from the feed used in the
Figure 1. Average and distribution of SH counts in samples collected from broiler caeca at 28 days of age in the different groups
(CFU/g caecum).
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experiment were all negative. The counts in the caecum
on day 28 are shown in Figure 1. The count values for
these assessments are presented in CFU per gram of
caecum. The count results <1.0 × 10² in caecum are
expressed as zero in Figure 1 because of the detection
limits of the technique used (count below 100/CFU/
g). Samples with a negative culture result were assigned
a value of 0 CFU/g in the statistical analysis. The aver-
age of quantitative counts and qualitative results in the
caeca in different treatments are presented in Table 2.
Table 3 presents the results of the qPCR used to detect
the vaccine strain in groups 1 and 3 in order to inves-
tigate shed bacteria. Faecal swabs taken at 2, 7, and 12
days after vaccination revealed that orally vaccinated
chickens were excreting the vaccine only at the first
two sampling times. Table 4 presents the statistical
assessments for isolation in spleen/liver and for body
weight on day 28. SH isolation in spleen/liver is pre-
sented as positive/negative and not as bacterial burden
because of difficulties in counting the low levels of
contamination in viscera compared with caecum. The
qualitative method was preferred to the quantitative
method for spleen/liver analysis because many samples
with low SH load would be considered negative as a
function of the limit of the technique used (quantifi-
cation only from 100 CFU/g). Normally for SH, the
level of contamination in caecum is higher than in
spleen/liver (Borsoi et al., 2011).
Discussion
Vaccination is the prominent means of controlling
non-typhoidal Salmonella sorovars; both inactivated
and live vaccines are widely adopted by the poultry
industry according to regional challenges and govern-
ing legislation (Van Immerseel et al., 2005; de Freitas
Neto et al., 2008; Majowicz et al., 2010; Berghaus
et al., 2011). However, the limited ability of vaccines
to act on the different serotypes that exist in the field
is well known, especially in the case of inactivated vac-
cines, which have a more specific action (Penha Filho
et al., 2009). Furthermore, live vaccines offer broader
protection that in turn grants more comprehensive
control, since cross-immunity may occur, depending
on the similarities between the involved serovars
(Hassan & Curtiss, 1994). The results presented in
Table 4 demonstrate the existence of a cross-immunity
conferred by Poulvac® ST, which significantly reduced
positive results in the liver/spleen of birds that were
experimentally inoculated at 3 days of age with a Bra-
zilian strain of SH when compared to the control
group. Studies with birds and other species have
demonstrated cross-immunity of live vaccines among
different serovars and the highest levels of protection
are found when the serovars involved have similarity
between their immunizing antigens (Heithoff et al.,
2001; Mohler et al., 2008). Cross-protection of live vac-
cines is an important benefit for poultry farmers, par-
ticularly in this case, where it eliminates the need for
another SH-specific vaccine.
However, when we analysed the SH count in the
caeca of birds challenged at 3 days of age (Figure 1),
we found that the existing numerical reduction was
not statistically significant, when compared to the con-
trol. This result agrees with studies that demonstrated a
direct correlation between earlier challenge and greater
difficulty in controlling infection through vaccination
(Poppe, 1999). As the vaccination occurred very
shortly before challenge, it is possible that the protec-
tion noted was due also to a non-specific increase in
innate immunity in response to the vaccination. In
this case as the challenge was very early, competitive
exclusion effect seems to have more importance (Van
Immerseel et al., 2005). This short window is not suffi-
cient for the birds to produce a complete adaptive
immune response. There will be no specific immunity
(such secretory IgA) at this time point. This reinforces
Table 2. Average of the quantitative counts (CFU) and
prevalence (positive %) of SH in the caecum on day 28.
Treatments
Average of the
quantitative
counts (CFU/g)
Prevalence
(positive %)
1 – Vaccinated and challenged at
3 days of age
1.26 × 105 12/20 (60.0%)
2 – Unvaccinated and challenged at
3 days of age
4.04 × 105 14/20 (70.0%)
3 – Vaccinated and challenged at
21 days of age
1.54 × 103 11/20 (55.0%)
4 – Unvaccinated and challenged at
21 days of age
6.35 × 104 12/20 (60.0%)
Table 3. Detection of Poulvac® ST vaccine strain using real-
time PCR of cloacal swab samples collected from broilers at
different times after vaccination.
Time Treatment 1 Treatment 3
3 days after (1st dose) vaccination (D03) 6/8 (75%) 6/8 (75%)
7 days after (1st dose) vaccination (D07) 6/8 (75%) 8/8 (100%)
12 days after (1st dose) vaccination (D12) 0/8 (0%) 0/8 (0%)
Table 4. Average body weight and SH presence (%) (conventional isolation methodology) in broilers liver and spleen at 28 days of
age (groups 1, 2, 3, and 4).
Treatments
Average weight (g)
at placement
Average weight (g)
at 28 days P-value/CV (%)
Liver/Spleen
positive (%) P-value
1 – Vaccinated and challenged at 3 days of age 48.63 1435.6 a 0.7885/10,24 0/20 (0.00) b 0.0033
2 – Unvaccinated and challenged at 3 days of age 48.54 1423.1 a 8/20 (40.00) a
3 – Vaccinated and challenged at 21 days of age 48.90 1449.0 a 0.9321/12,67 1/20 (5.00) a 0.1818
4 – Unvaccinated and challenged at 21 days of age 48.77 1441.1 a 5/20 (25.00) a
Notes: Different letters indicate significant difference at P≤ 0.05 using F test for average body weight or differ statistically by Fisher’s exact test for liver/
spleen positive presence of SH in two-sided alternative hypothesis.
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the fact that birds must be immunized as soon as
possible before challenge, during the first days of life,
so that they have time to develop immunity. This is
often difficult, since production environments are
often contaminated and flocks can be challenged as
soon as they are housed (personal communication of
Manfio, 2012).
Moreover, the statistically insignificant results of the
samples taken from the caeca of the birds challenged at
3 days (Figure 1) also corroborate that control of Sal-
monella infection within the intestine is harder to
achieve than in the case of infection in the viscera,
since the reach of the immune response depends on
local mucosal immunity. Secretory IgA participates
directly in local immunity, since this antibody is
secreted into the mucosal surface of the intestine and
helps reduce bacterial colonization in the intestinal
lumen (Pasetti et al., 2011). In addition, cell-based
immune responses where CD8+ T cells are activated
as the result of live vaccines are more effective when
compared to high levels of antibodies in the serum of
birds that were inoculated with inactivated vaccines
(Penha Filho et al., 2012). Experiments with inactivated
vaccines have shown significant reduction of coloniza-
tion by Salmonella in organs, but the intestinal tract
may still be susceptible to colonization. Therefore, it
is more difficult to prevent colonization in this organ
than in others (Adriaensen et al., 2007).
The SH count in the vaccinated group, which was
challenged at 21 days of age, was significantly less
(P≤ 0.05) than in the control group (Figure 1), show-
ing the vaccine’s ability to also reduce intestinal coloni-
zation, since two doses were given before the challenge.
Both the innate immune system and the specific immu-
nity conferred by vaccination with live vaccine help
prevent intestinal colonization, and the later the chal-
lenge takes place, the greater the effectiveness of the
vaccination programme (McSorley, 2014). Although
the differences in prevalences between the vaccinated
and control groups were not statistically significant,
there was a reduction in the percentage of positive
liver/spleen results in birds inoculated at 21 days of
age, indicating a beneficial trend from the use of the
vaccine to reduce visceral contamination (Table 4).
Insufficient colonization of the unvaccinated group
(only 25%) was a limitation of this study, which, if
higher, could have brought the significance values
below the 0.05 threshold.
The mutation of the aroA gene of the Poulvac® ST
vaccine resulted in functional loss of phosphoenolpyr-
uvyl-shikimate-5-phosphate synthase, an enzyme
required for biosynthesis of aromatic amino acids.
This auxotrophic mutation can be compensated in
vitro by supplementation of phenylalanine, trypto-
phan, and tyrosine. However, since these amino acids
are not available for the Salmonella vaccine in the
host tissue, this results in attenuation during growth
in vivo (Coloe et al., 1994). Consequently, the Poulvac®
ST vaccine shows self-limiting behaviour where it
remains viable in the bird for a restricted time, but
long enough to trigger a cellular immune response.
Analysis using specific qPCR in this experiment
showed the vaccine’s ability to survive for a limited
time in the intestines of the birds (Table 3). These
data agree with research conducted on the original
STM-1 strain of the vaccine (Alderton et al., 1991).
After a period of 12 days post-vaccination of first
dose, the birds were not detected as bearers of the
agent from the Poulvac® ST vaccine (Table 3). It was
possible to detect the “vaccine uptake” up to the
seventh day of life in the birds when the specific PCR
was conducted on Poulvac® ST vaccine. This length
of time would be sufficient to stimulate local and sys-
temic immunity, preferably prior to the field challenge.
In addition, studies show that during the time that live
vaccines remain in the intestine, there is a potential
mechanism of protection by bacteriological competi-
tive exclusion (Van Immerseel et al., 2005). Future
studies should investigate if live vaccines mimic field
infection, invading the host organism and reaching
internal organs in the same way the field strain does.
For some time, great efforts have been made towards
developing this type of vaccine with gene deletion
because even though these are live salmonellas and
therefore retain the field challenging behaviour during
initial infection, they are also extremely safe as they do
not persist in poultry or even in the environment for
long periods of time (Hoiseth & Stocker, 1981; Barrow
et al., 1990; Hormaeche et al., 1991; Cooper et al., 1994;
Tan et al., 1997; Van Immerseel et al., 2002). Thus, the
great advantage of genetically modified live vaccines is
the low risk of reversion to virulence in comparison to
vaccines made from attenuated rough strains, for
example (Frey, 2007; Matsuda et al., 2010; Penha
Filho et al., 2010; Matsuda et al., 2011a, b; Shehata
et al., 2013; Van Immerseel et al., 2013).
In the assessed experimental conditions, there was
no statistical difference (P > 0.05) for the variable
weight in the different treatments, even in birds that
were only challenged with SH (Table 4). These results
are in agreement with recent studies indicating that
various non-typhoidal Salmonella serovars are highly
adapted to the host and do not cause a reduction in
performance parameters (Setta et al., 2012; Muniz
et al., 2015). This asymptomatic behaviour makes
the control of these serovars more difficult because
contaminated flocks generally are infected without
demonstrating clinical signs that are visible to
producers.
The results of this experimental study demonstrate
that genetically modified live vaccines can be a useful
and safe tool for controlling SH in poultry. Vaccination
with Poulvac® ST was able to partially decrease the bac-
terial load of SH in both the caecum and liver/spleen
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after oral challenge. However, it is important to know
their characteristics and limitations, in order to use
them effectively. According to the results of this trial,
the efficacy of cross-protection to SH depends on at
least two applications of the vaccine. Future studies
are recommended to indicate the duration of this
immunity, as the test was only conducted 7 days fol-
lowing vaccination.
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